Off-label use patterns of glucagon-like peptide-1 receptor agonists: a systematic review
Abstract Background The increasing off-label use of glucagon-like peptide-1 receptor agonists, including Semaglutide and Tirzepatide, has generated significant clinical and ethical debate. Originally approved for Type 2 Diabetes, these agents are increasingly prescribed for weight management in individuals without diab...